• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Pfizer

Pfizer

Pfizer Inc PFE

Last Price$35.09Day Change (%)0.20%
Open Price$35.14Day Change ($)0.07
Day Range34.94–35.1952-Week Range28.25–36.46

As of Thu 6/30/2016 12:51:00 PM | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. Sources Say Fresenius May Acquire Pfizer Medical Devices Arm for About $1.5 Billion

    Sources Say Fresenius May Acquire Pfizer Medical Devices Arm for About $1.5 Billion

  2. Pfizer Announces FDA Advisory Committees’ Recommend ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride) Extended-Release Capsules for Approval

    Pfizer Announces FDA Advisory Committees’ Recommend ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride) Extended-Release Capsules for Approval

  3. ICON Announces Service Agreement with Pfizer

    ICON Announces Service Agreement with Pfizer

  4. Merck and Pfizer Announce Two Pivotal Phase 3 Studies for Ertugliflozin, an Investigational SGLT-2 Inhibitor, Met Primary Endpoints, Showing Significant A1C Reductions in Patients with Type 2 ...

    Merck and Pfizer Announce Two Pivotal Phase 3 Studies for Ertugliflozin, an Investigational SGLT-2 Inhibitor, Met Primary Endpoints, Showing Significant A1C Reductions in Patients with Type 2 Diabetes

  5. Hormone Replacement Therapy (HRT) - Global Strategic Business Report 2016-2022: Amid Controversies, Confusion and Competition, Demand for HRT Continues to Rise - Research and Markets

    Hormone Replacement Therapy (HRT) - Global Strategic Business Report 2016-2022: Amid Controversies, Confusion and Competition, Demand for HRT Continues to Rise - Research and Markets

  6. Evotec and Ellersbrook Join Forces to Accelerate TargetNASH

    Evotec and Ellersbrook Join Forces to Accelerate TargetNASH

  7. Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

    Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

  8. Pfizer Prices $5.0 Billion Debt Offering

    Pfizer Prices $5.0 Billion Debt Offering

  9. Pfizer Files 8K - Other Events

    Pfizer Files 8K - Other Events

  10. Pfizer Files 8K - Other Events

    Pfizer Files 8K - Other Events

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.